The investigators plan to carry out an experimental study on the preventive effect of recombinant human interferon alpha nasal drops on the infection of 2019 new coronavirus in medical staff.
The investigators plan to carry out an experimental study enrolling more than 2000 medical
staff and divide participants into low-risk group and high-risk group according to whether
they can directly exposed to 2019-nCOV infected patients. In the low-risk group, participants
will be given recombinant human interferon alpha-1b nasal drops (2-3 drops/nostril/ time, 4
times/ day), and in the high-risk group will be given preventive intervention with interferon
nasal drops and thymosin-α (thymosin was injected subcutaneously once / week), and the
intervention time is 28 days.
Drug: recombinant human interferon Alpha-1b
recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.
Other Name: interferon α
Drug: thymosin alpha 1
thymosin alpha 1 subcutaneous injection 1 time per week.
Other Name: thymosin α
Inclusion Criteria:
- Formally serving medical staff in Taihe Hospital;
Exclusion Criteria:
- pregnant women;
- severe chronic diseases who are unable to participate in daily routine work;
- fever (temperature≥37.3 ° ) and / or respiratory symptoms.
Taihe Hospital
Shiyan, Hubei, China
Investigator: Zhongji Meng
Contact: +86-18971905757
zhongji.meng@163.com
Zhongji Meng
18971905757
zhongji.meng@163.com